Rocket Pharmaceuticals (RCKT) Stock Forecast & Price Target

RCKT Forecast - Frequently Asked Questions

What is Rocket Pharmaceuticals' forecast for 2026?

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Rocket Pharmaceuticals is $13.86, with a high forecast of $44.00 and a low forecast of $3.00.

Should I buy or sell Rocket Pharmaceuticals stock right now?

18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last year. There are currently 3 sell ratings, 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" RCKT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RCKT, but not buy additional shares or sell existing shares.

Does Rocket Pharmaceuticals's stock price have much upside?

According to analysts, Rocket Pharmaceuticals's stock has a predicted upside of 258.99% based on their 12-month stock forecasts.

Has Rocket Pharmaceuticals been upgraded by Wall Street analysts recently?

Over the previous 90 days, Rocket Pharmaceuticals's stock had 2 upgrades by analysts.

What analysts cover Rocket Pharmaceuticals?

Rocket Pharmaceuticals has been rated by research analysts at Bank of America, Cantor Fitzgerald, Chardan Capital, Lifesci Capital, The Goldman Sachs Group, and Weiss Ratings in the past 90 days.

Do Wall Street analysts like Rocket Pharmaceuticals more than its competitors?

Analysts like Rocket Pharmaceuticals more than other "medical" companies. The consensus rating score for Rocket Pharmaceuticals is 2.39 while the average consensus rating score for "medical" companies is 2.30. Learn more on how RCKT compares to other companies.